Physician profile
Ashlynn Davis
NPI 1386386985
$1,337.98
in general payments reported to CMS, 2019-2025
14 companies · $332 in 2025
The $332 reported for 2025 was more than what 80% of Psychiatric/Mental Health, Adult (Registered Nurse) providers received nationally (typical 2025 total: $121).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $304 · 2023: $457 · 2024: $244 · 2025: $332.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $956 · Education: $78.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $955.67 |
| Education | $78.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $318.57 | 2022-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Teva Pharmaceuticals USA, INC. | $230.41 | 2023-2025 | Uzedy, Austedo Xr, Austedo |
| Janssen Pharmaceuticals, INC | $142.06 | 2022-2024 | Invega Sustenna, Invega Trinza, Invega |
| Abbvie INC. | $135.64 | 2022-2025 | |
| Alkermes, INC. | $126.96 | 2022-2025 | Aristada, Lybalvi |
| E.R. Squibb & Sons, L.L.C. | $79.60 | 2024-2025 | Cobenfy |
| Lundbeck LLC | $64.64 | 2024-2025 | Abilify Asimtufii, Rexulti |
| Neurocrine Biosciences, INC. | $61.68 | 2022-2025 | Ingrezza |
| Indivior INC. | $42.27 | 2023 | Perseris |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $39.75 | 2022-2023 | |
| Axsome Therapeutics, INC. | $35.20 | 2022-2023 | Auvelity |
| Vanda Pharmaceuticals INC. | $24.91 | 2022 | |
| Corium, LLC | $20.19 | 2022 | |
| Noven Therapeutics, LLC | $16.10 | 2023 | Secuado, Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashlynn Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.